Protein Allostery in Rational Drug Design

被引:8
|
作者
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, Sakai, Osaka, Japan
来源
关键词
Protein kinase; Allosteric inhibitor; Structure-based drug discovery; High selectivity; CRYSTAL-STRUCTURES; KINASE INHIBITORS; BINDING; IDENTIFICATION; TARGET; POTENT; SITE; SELECTIVITY; MECHANISM; CK2-ALPHA;
D O I
10.1007/978-981-13-8719-7_3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This chapter focuses on protein kinases that transfer the phosphate group of ATP to the hydroxyl group of a substrate protein. Five hundred eighteen human protein kinases are classified into serine/threonine kinases and tyrosine kinases and individually or synergistically transduce physiologic stimuli into cell to promote cell proliferation or apoptosis, etc. Protein kinases are identified as drug targets because dysfunction of kinases leads to severe diseases such as cancers and autoimmune diseases. A large number of the crystal structures of the protein kinase inhibitor complex are available in Protein Data Bank and facilitated the drug discovery targeting protein kinases. The protein kinase inhibitors are classified into categories, Type-I, Type-II, Type-III, Type-IV, and Type-V, and as a separate class, covalent-type inhibitors. In any type, a protein kinase inhibitor bound to the allosteric region is advantageous in terms of selectivity compared to the traditional ATP-competitive one. In the following sections, the successful and promising examples of the partially or fully allosteric protein kinase inhibitors are illustrated in the following pages.
引用
收藏
页码:45 / 64
页数:20
相关论文
共 50 条
  • [41] Advances in rational drug design methods
    Simons, S
    GENETIC ENGINEERING NEWS, 2002, 22 (20): : 22 - +
  • [42] New technologies and rational drug design
    Skotnicki, JS
    Jacobs, RS
    THERAPEUTIC STRATEGIES FOR MODULATING THE INFLAMMATORY DISEASES, 1998, 49 : 91 - 93
  • [43] Chemogenomic approaches to rational drug design
    Rognan, D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (01) : 38 - 52
  • [44] Progress in the Rational Design for Polypharmacology Drug
    Zhou, Jinming
    Li, Quanjie
    Wu, Meng
    Chen, Chao
    Cen, Shan
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (21) : 3182 - 3189
  • [45] The growing allure of rational drug design
    Liszewski, K
    GENETIC ENGINEERING NEWS, 2005, 25 (06): : 35 - 37
  • [46] RATIONAL DRUG DESIGN - MIRAGE OR MIRACLE
    BELLEAU, B
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1970, 103 (08) : 850 - &
  • [47] ANTIBODIES AS MODELS FOR RATIONAL DRUG DESIGN
    HABER, E
    BIOCHEMICAL PHARMACOLOGY, 1983, 32 (13) : 1967 - 1977
  • [48] Rational design of drug materials and drug delivery systems
    Bowker, Michael
    European Journal of Pharmaceutical Sciences, 2002, 15 (01) : 97 - 98
  • [49] New approaches to rational drug design
    Farber, GK
    PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) : 327 - 332
  • [50] Search techniques for rational drug design
    Finn, PW
    Kavraki, LE
    Latombe, JC
    Motwani, R
    Venkatasubramanian, S
    INTELLIGENT INFORMATION SYSTEMS, (IIS'97) PROCEEDINGS, 1997, : 2 - 6